Maher M. Haddad

Array ( [id] => 20622645 [patent_doc_number] => 12590144 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Cardiac troponin I specific antibody, kit and uses thereof [patent_app_type] => utility [patent_app_number] => 18/479371 [patent_app_country] => US [patent_app_date] => 2023-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 1433 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18479371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034191 [patent_doc_number] => 20240084006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47 [patent_app_type] => utility [patent_app_number] => 18/477254 [patent_app_country] => US [patent_app_date] => 2023-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003654 [patent_doc_number] => 20240067725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => MONOCLONAL ANTIBODY AGAINST HUMAN LAG-3, METHOD FOR PREPARING SAME, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/472144 [patent_app_country] => US [patent_app_date] => 2023-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172488 [patent_doc_number] => 20240158462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES FOR USE IN DETERMINING PRESENCE AND OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES [patent_app_type] => utility [patent_app_number] => 18/244259 [patent_app_country] => US [patent_app_date] => 2023-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18244259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955189 [patent_doc_number] => 20240043516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 18/242215 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 335 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18242215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111235 [patent_doc_number] => 20240122985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS [patent_app_type] => utility [patent_app_number] => 18/459995 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 158977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034220 [patent_doc_number] => 20240084035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS [patent_app_type] => utility [patent_app_number] => 18/457177 [patent_app_country] => US [patent_app_date] => 2023-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18457177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127252 [patent_doc_number] => 20240132605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => ANTIBODIES, USES & METHODS [patent_app_type] => utility [patent_app_number] => 18/364906 [patent_app_country] => US [patent_app_date] => 2023-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18364906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20593613 [patent_doc_number] => 12577315 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Antibodies to CD40 with enhanced agonist activity [patent_app_type] => utility [patent_app_number] => 18/362625 [patent_app_country] => US [patent_app_date] => 2023-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 29178 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18362625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112838 [patent_doc_number] => 20240124588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => COMPOSITIONS AND METHODS FOR DISABLING MYELOID CELLS EXPRESSING TREM1 [patent_app_type] => utility [patent_app_number] => 18/361780 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097795 [patent_doc_number] => 20240117023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => METHOD [patent_app_type] => utility [patent_app_number] => 18/356305 [patent_app_country] => US [patent_app_date] => 2023-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18356305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754063 [patent_doc_number] => 20230357435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES [patent_app_type] => utility [patent_app_number] => 18/355839 [patent_app_country] => US [patent_app_date] => 2023-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18355839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20622658 [patent_doc_number] => 12590157 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments [patent_app_type] => utility [patent_app_number] => 18/355975 [patent_app_country] => US [patent_app_date] => 2023-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7624 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18355975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20480397 [patent_doc_number] => 12528868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => CD1a antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 18/354934 [patent_app_country] => US [patent_app_date] => 2023-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 16 [patent_no_of_words] => 62245 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18354934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217860 [patent_doc_number] => 20240182564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND [patent_app_type] => utility [patent_app_number] => 18/354611 [patent_app_country] => US [patent_app_date] => 2023-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18354611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020192 [patent_doc_number] => 20240076363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/349027 [patent_app_country] => US [patent_app_date] => 2023-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19188156 [patent_doc_number] => 20240167069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => Sialylated Glycoproteins [patent_app_type] => utility [patent_app_number] => 18/218996 [patent_app_country] => US [patent_app_date] => 2023-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18218996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971954 [patent_doc_number] => 20240052046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/344711 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55204 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 1182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217877 [patent_doc_number] => 20240182581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS [patent_app_type] => utility [patent_app_number] => 18/344724 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897887 [patent_doc_number] => 12275793 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders [patent_app_type] => utility [patent_app_number] => 18/341202 [patent_app_country] => US [patent_app_date] => 2023-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 1127 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 208 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18341202 [rel_patent_id] =>[rel_patent_doc_number] =>)